BARCELONA, Spain — Adding bone-targeting radium-223 (Ra223) to the androgen receptor pathway inhibitor enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer and bone metastases significantly […]

Several new clinical trials in breast cancer have opened in recent months. Perhaps one of your patients could benefit from taking part? Human epidermal growth factor […]

At a conference on hematologic oncology, two sickle cell experts faced off in a debate about whether gene therapy or alternative stem-cell transplant is the best […]

BARCELONA, Spain — Adding retifanlimab, an anti–programmed cell death 1 (PD-1) monoclonal antibody, to carboplatin plus paclitaxel in inoperable locally recurrent or metastatic squamous cell carcinoma […]

SAN DIEGO — New research highlights a mismatch between lung cancer screening eligibility criteria and actual lung cancer risk, which means many patients who develop lung […]

Burnout, a syndrome caused by work overload, is one of the main challenges in the medical profession. Although it is a general problem, certain professionals, such […]

The addition of nivolumab to rucaparib did not lead to better progression-free survival than rucaparib monotherapy in patients with newly diagnosed, advanced, high-grade ovarian cancer (AHGOC), […]